Despite efforts to find more effective treatments, equine peritonitis remains one of the surgical clinical conditions of increased mortality, requiring studies for adoption of more effective therapeutic strategies that result in the increase of the affected animal survival rate. Relying on the fact unpublished preliminary study in FMVZ-UNESP / Botucatu, SP shows that the use of ceftriaxone intraperitoneally provides high drug concentrations (above the minimum inhibitory concentration) for longer than the 24 hours, and the apparent effectiveness obtained in some clinical cases, this study aims to evaluate the first time in systematic study, treatment with intraperitoneal ceftriaxone on clinical, laboratory, microbiological, sonographic and clinical outcome in cases of peritonitis in horses. Are included in the study horses with clinical signs of peritonitis associated with nucleated cells e 10,000 / uL and / or protein e 2,3 g / dL, associated with the difference of 50 mg / dL concentration between the blood and peritoneal glucose. After inclusion in the study, peritoneal fluid of these animals will be submitted to microbiological culture and antimicrobial susceptibility testing "in vitro". The animals will receive supportive therapy associated with five days of intraperitoneal ceftriaxone therapy at a dose of 25 mg / kg every 24 hours. This antimicrobial agent may be used alone or in combination with other systemic antibiotics, according to the individual conduct of the veterinarian responsible for the care. In order to monitor the clinical response due to therapy will be performed serial evaluations of: physical examination; behavior; blood count and analysis of peritoneal fluid; concentration of serum amyloid A; glucose and lactate levels; blood gas analysis and sonographic evaluation. Considering the fact ceftriaxone be an antibiotic of broad spectrum bound to plasma proteins, while the fixed and free form in equilibrium concentration-dependent, and that the free form is the active portion of ceftriaxone, are necessary high systemic doses to achieve the desired therapeutic effect. Thus, the use of ceftriaxone intraperitoneally in horses, may result in increased availability of free drug, could lead not only to amplify the therapeutic effect, but also to better clinical outcomes.
News published in Agência FAPESP Newsletter about the scholarship: